It may be moot, since NGIO is not trading yet, but
Post# of 36537
I continue to believe that Generex needs to consolidate. They have too many irons in the the fire and have not shared the priorities with shareholders. Are we and MSO, R&D company, orthopedic and wound product provider, or something else? We cannot be all of these with such limited funding. We keep asking, "What's the story with the S-1?" "Where's the money?" "Are we doomed to OTC forever, or can we finally return to NASDAQ?"